統合失調症患者の就労に関連する要因の抽出 by HASEGAWA, Tadashi & 長谷川, 直
Identifying improvable employment-related 
factors in schizophrenia patients 
（統合失調症患者の就労に関連する要因の抽出）
千葉大学大学院医学薬学府
先端医学薬学専攻
（主任：伊豫雅臣	 教授）
長谷川直
ABSTRACT 
Although many studies report various factors related to future employment 
of schizophrenia patients, few identify the treatable or improvable ones. The 
responses to the first year of treatment and daily antipsychotic drug doses 
may be the treatable and improvable factors. We surveyed 235 schizophrenia 
outpatients in three facilities, of whom 129 and 106 were employed and 
unemployed, respectively. Through face-to-face interviews and medical 
record reviews, we investigated symptomatic and social functioning 
responses to the first year of treatment using the Global Assessment of 
Psychopathology Scale (GAPS) and the Social and Occupational Functioning 
Assessment Scale (SOFAS). We investigated daily antipsychotic drug doses 
and other clinical assessments at the interview time. Finally, we used 
multivariable logistic regression analysis. SOFAS-measured improvements 
in the period 6 to 12 months after beginning treatment and daily 
antipsychotic drug doses equivalent to less than 600 mg of chlorpromazine 
were identified as an employment-related factor, but GAPS-measure 
improvements were not. Social functioning improvements in the period 6 to 
12 months after beginning treatment and low-to-moderate daily 
antipsychotic drug doses were detected as employment-related factors, 
suggesting that early efforts to improve social functioning and optimize 
antipsychotic drug doses could lead to future employment for schizophrenia 
patients. 
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1. Introduction 
Employment in society is highly important for recovery in schizophrenia 
patients (Andreasen et al., 2005; Schennach et al., 2012; Secker et al., 2001; 
Üçok et al., 2012). Schizophrenia patients face employment rates as low as 8 
to 35% in various countries including Japan (Anthony et al., 1987; Brekke et 
al., 1993; Gaite et al., 2002; Marwaha et al., 2004; Ministry of Health, 
Labour and Welfare 2010; Rogers et al., 1988). It is important to identify the 
factors critical to their employment.  
Previously reported employment-related factors for schizophrenia 
patients include cognitive impairment, negative symptoms, youth, education, 
experience of employment, marital status, sex, remission duration, and 
public support/disability income (Tsang et al., 2010; Üçok et al., 2012). 
However, few studies have tried to identify the clinically improvable or 
treatable factors. 
Studies on recovery from schizophrenia serve as useful starting points for 
identifying such factors. Previous studies have reported that early support 
during the first 2–5 years from the onset of illness is related to recovery from 
schizophrenia (Birchwood et al., 1998) and that early improvements in 
psychiatric symptoms and social functioning (Verma et al., 2012; Lambert et 
al., 2008; Ascher-Svanum et al., 2008; Emsley et al., 2008; Kinon et al., 2010) 
promote overall psychiatric and social function recovery. Furthermore, 
Kopelowicz et al. (2005) reported that patients who recovered from 
schizophrenia had received lower antipsychotic dosages than those who did 
not recover. These findings provide useful clues for identifying improvable 
employment-related factors in patients with schizophrenia. 
Other reported recovery-related factors include resilience (Hofer et al., 
2016; Bozikas et al., 2016), insight (Lysaker et al., 1998), depressive 
symptoms (Brekke et al., 1993; Mueser et al., 1997), and the duration of the 
untreated period (DUP) (Bottlender et al., 2003; Harrigan et al., 2003; 
Harris et al., 2005; Boden et al., 2009). These may also be 
employment-related factors in patients with schizophrenia. 
We aimed to identify the improvable employment-related factors for 
schizophrenia patients by surveying outpatients receiving treatment. We 
hypothesized that daily antipsychotic drug doses and early symptomatic or 
social function responses to treatment would be related to employment. 
Furthermore, we examined whether resilience, insight, depressive symptoms, 
and the DUP were related to employment status in patients with 
schizophrenia. 
 
2. Methods 
2.1. Participants and definition of employment 
This study was approved by the institutional review boards of all 
participating research facilities. Written informed consent was obtained 
from all participants after they received a full explanation of the procedure 
including potential risks and benefits. This study was conducted from 
October 2011 to June 2014 in three different facilities: Chiba University 
Hospital (urban area), Chiba Psychiatry Medical Center (urban area), and 
Sodegaura Satsukidai Hospital (rural area). Our inclusion criteria were (1) 
an age from 18 to 65 years, (2) a diagnosis of schizophrenia or schizoaffective 
disorder according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition, Text Revision (American Psychiatric Association, 
2000), and (3) outpatient status. A diagnosis of comorbid mental retardation 
or dementia was an exclusion criterion. 
We defined employment in society as (1) working in a full-time or 
part-time job or (2) being self-employed in one’s own business or profession. 
We excluded participants engaged in work rehabilitation. Those meeting the 
criteria for employment in society formed the employed group, and the 
others formed the unemployed group. 
2.2. Study design and procedure 
This study was cross-sectional. We first surveyed outpatients with 
schizophrenia or schizoaffective disorder at three facilities and determined 
their employment status according to the criteria in 2.1. We then collected 
the required clinical information described in 2.3 through both retrospective 
examinations of medical records and face-to-face interviews with 
participants and their families. 
2.3. Assessments 
2.3.1 Clinical response to initial treatment 
To assess each patient’s clinical response to initial treatment, we used the 
Global Assessment of Functioning Scale (American Psychiatric Association, 
2000), which rates functioning on a numeric scale (1 through 100) in 10-point 
bands from severe psychiatric symptoms and poor functioning to mild 
psychiatric symptoms and high functioning. We also used the Social and 
Occupational Functioning Assessment Scale (SOFAS) to assess social 
functioning and the Global Assessment of Psychopathology Scale (GAPS) to 
assess psychiatric symptom severity, as in previous studies (Goldman et al., 
1992; Pedersen et al., 2007; Smith et al., 2011). We retrospectively measured 
SOFAS and GAPS scores at the following three timepoints: the first 
consultation with a psychiatrist (T0), 6 months after beginning treatment 
(T1), and 12 months after beginning treatment (T2) (Fig. 1).  
2.3.2 Daily antipsychotic drug doses as chlorpromazine-equivalent doses 
We determined all participants’ daily antipsychotic drug doses at the 
interview (Fig. 1) by reviewing medical charts and converted each daily dose 
to a chlorpromazine (CP)-equivalent dose according to a published method 
(Inagaki and Inada, 2008). We classified CP-equivalent doses lower than 600 
mg/day as low-to-moderate and those higher as high because 
treatment-resistant schizophrenia is defined as the need for doses greater 
than 600 mg/day (Juarez-Reyes et al., 1995; Suzuki et al., 2012). 
2.3.3. Other clinical assessments 
We investigated several clinical assessments used in previous studies. 
Because a systematic review (Tsang et al., 2010) identified negative 
symptoms as an employment-related factor, we measured 
schizophrenia-related psychiatric symptoms and psychopathology using the 
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1988). Previous 
studies found that depressive symptoms correlated with cognitive 
dysfunction, which is strongly related to unemployment (Brekke et al., 1993; 
Mueser et al., 1997), so we measured the severity of depressive symptoms 
using the Japanese version of the Calgary Depression Scale for 
Schizophrenia (JCDSS) (Addington et al., 1996; Kaneda et al., 2000). 
Because previous studies have showed that high resilience patients could 
lead to recovery (Hofer A et al. 2016) and that resilience may influence 
SOFAS scores in patients with schizophrenia (Bozikas VP et al., 2016), we 
measured resilience using the Connor–Davidson Resilience Scale (CDRS) 
(Connor and Davidson, 2003). Poor insight is reportedly associated with 
social functions, especially the maintenance of interpersonal relationships 
(Lysaker PH et al., 1998), so we measured insight using the Japanese 
version of the Schedule for Assessments of Insight (SAI-J) (David, 
1990; Sakai et al., 2000). The DUP is reportedly a strong predictor of 
outcomes in the social function and psychiatric symptom domains 
(Bottlender et al., 2003; Harrigan et al., 2003; Harris et al., 2005; Boden et 
al., 2009), so we also assessed it.  
2.4. Statistical analysis 
For the patients’ characteristics, summary statistics were constructed as 
frequencies and proportions for categorical data and means and standard 
deviations for continuous variables. The baseline variables were compared 
using a chi-square test for categorical outcomes and an unpaired t-test for 
continuous variables.  
To compare the employed and unemployed groups’ clinical responses to 
initial treatment, the SOFAS and GAPS scores assessed from T0 to T2 were 
analyzed using a mixed effects model for repeated measures (MMRM) 
analysis (Gueorguieva and Krystal, 2004). To detect the employment-related 
factors, we used a multivariable logistic regression analysis with the 
simultaneous method. Employment status was set as the dependent variable, 
while the independent variables were the CP-equivalent drug dose, PANSS 
negative symptoms score, JCDSS total score, CDRS total score, SAI-J total 
score, sex, years of education, work history, disease duration, and half-year 
changes in SOFAS and GAPS scores. Statistical significance was defined as 
p < 0.05. These analyses were performed using SPSS Version 21.0 for 
Macintosh (IBM; Armonk, NY).  
 
3. Results 
The employment rate was 20% (255/1254) among all outpatients with 
schizophrenia or schizoaffective disorder at the three facilities. Of the 1254 
outpatients, 235 (129 employed and 106 unemployed) participated in this 
study. The participants’ demographic and clinical characteristics are shown 
in Table 1. 
 3.1. Clinical response to initial treatment  
MMRM analysis of SOFAS scores showed that the employed group 
exhibited significantly greater improvements than the unemployed group at 
both T1 (mean inter-group difference: 4.732, 95% confidence interval [CI]: 
0.837–8.627, p = 0.018) and T2 (7.048, 95% CI: 2.652–11.44, p = 0.002) (Fig. 
2.1). Similarly, MMRM analysis of GAPS scores showed that the employed 
group exhibited significantly greater improvements than the unemployed 
group at both T1 (7.147, 95% CI: 2.776–11.52, p = 0.0015) and T2 (9.338, 95% 
CI: 4.554–14.12, p = 0.0002) (Fig. 2.2). 
3.2. Daily doses of antipsychotic drugs 
As shown in Table 1, the employed group had significantly lower (p < 1.0 
× 10-6) daily CP-equivalent drug doses than the unemployed group. The 
mean difference was -272.2 mg/day (95% CI: -367.1 to -177.3). 
3.3. Other clinical assessments 
As showed in Table 1, compared to the unemployed group, the employed 
group had significantly more years of education (p = 0.044), shorter disease 
durations (p = 0.012), lower PANSS scores (total, positive, and negative) (p < 
1.0×10-6), higher CDRS total scores (p < 1.0×10-6), and lower JCDSS total 
scores (p = 0.014). The groups were not significantly different in age (p = 
0.130), sex (p = 0.210), work history (p = 0.301), age at onset (p = 0.086), DUP 
(p = 0.396), marital status (p = 0.486), or SAI-J total score (p = 0.172).  
3.4. Employment-related factors in multivariable logistic regression analysis 
Our multivariable logistic regression analysis determined that half-year 
changes in SOFAS and GAPS scores had a strong positive correlation with 
each other. The Pearson correlation coefficients were 0.642 for the T0-to-T1 
changes (p < 1.0×10-6) and 0.662 for the T1-to-T2 changes (p < 1.0×10-6). We 
therefore conducted multivariable logistic regression analyses using SOFAS 
scores alone and GAPS scores alone. 
In our logistic regression analysis using only SOFAS scores, the model 
significantly (χ2 = 113.553, df = 11, p < 1.0×10-6) and correctly predicted the 
employment status of 82.5% of the subjects (Cox and Snell R2 = 0.443). The 
critical employment-related factors were T1-to-T2 SOFAS score 
improvements (OR: 1.730, 95% CI: 1.136–2.634, p = 0.011), low-to-moderate 
daily CP-equivalent doses (OR: 3.425, 95% CI: 1.470–7.981, p = 0.004), male 
sex (OR: 3.697, 95% CI: 1.462–9.349, p = 0.006), low PANSS negative 
symptom scores (OR: 0.799, 95% CI: 0.736–0.867, p < 1.0×10-6), high CDRS 
total scores (OR: 1.046, 95% CI: 1.018–1.075, p = 0.001), and short disease 
durations (OR: 0.936, 95% CI: 0.893–0.980, p = 0.005) (Table 2.1).  
In our logistic regression analysis using only GAPS scores, the model 
significantly (χ2 = 108.883, df = 11, p < 1.0×10-6) and correctly predicted the 
employment status of 80.9% of the subjects (Cox and Snell R2 = 0.430). The 
critical employment-related factors were low-to-moderate CP-equivalent 
doses (OR: 3.335, 95% CI: 1.454–7.649, p = 0.004), male sex (OR: 3.203, 95% 
CI: 1.315–7.800, p = 0.010), low PANSS negative symptom scores (OR: 0.796, 
95% CI: 0.733–0.864, p < 1.0×10-6), high CDRS total scores (OR: 1.042, 95% 
CI: 1.016–1.069, p = 0.002), and short disease durations (OR: 0.947, 95% CI: 
0.904–0.991, p = 0.018) (Table 2.2).  
 
4. Discussion 
We hypothesized that daily antipsychotic drug doses and early 
symptomatic or social function responses to treatment would be related to 
future employment in schizophrenia patients. This study partly confirmed 
our hypotheses. First, social functioning improvements in the period 6 to 12 
months after beginning treatment significantly contributed to future 
employment, though improvements in the first 6 months did not. Second, 
low-to-moderate antipsychotic drug doses were also an employment-related 
factor.  
This is the first report to specifically identify social functioning 
improvements in the period 6 to 12 months after beginning treatment as a 
factor leading to future employment in society for schizophrenia patients. 
This is consistent with previous reports of the relationship between early 
social functioning improvement and recovery in schizophrenia patients 
(Álvarez-Jiménez et al., 2012; Lambert et al., 2008). There is a pressing need 
to identify the factors related to employment in schizophrenia patients, as 
shown by the low employment rate (20%) of patients in this study and the 
similarly low rates in previous studies (Anthony et al., 1987; Brekke et al., 
1993; Gaite et al., 2002; Marwaha et al., 2004; Ministry of Health, Labour 
and Welfare 2010; Rogers et al., 1988). Therefore, our findings indicate that 
improvements in social functioning during early-stage schizophrenia 
treatment promote future employment in society. Further research into 
employment-related factors in patients with schizophrenia is needed. 
This study also showed that psychiatric symptom improvements during 
the first year of treatment were not contributing factors to future 
employment in schizophrenia patients. This finding is inconsistent with 
some previous studies that reported that symptomatic responses to the first 
2 weeks to 3 months of treatment may predict recovery in schizophrenia 
patients (Ascher-Svanum et al., 2008; Lambert et al., 2008; Verma et al., 
2012). However, our finding is partly consistent with the suggestion from 
Tsang et al. (2010) that positive symptoms do not predict employment status. 
Velligan et al. (2009), however, reported that negative symptoms predict 
functional outcomes. Further research is needed to investigate the 
relationship between symptomatic response to initial treatment and future 
employment status in schizophrenia patients with consideration of positive 
and negative symptoms.  
This study showed that low-to-moderate daily antipsychotic drug doses, 
defined as CP-equivalent doses lower than 600 mg/day, were an 
employment-related factor in schizophrenia patients. This is the first report 
to identify the relationship between daily antipsychotic drug doses and 
employment. Several studies have reported that cognitive impairment is 
correlated with increasing antipsychotic drug doses (Sakurai et al., 2013; 
Takeuchi et al., 2013). Our findings are therefore consistent with reports 
that the inability to work in society is strongly associated with cognitive 
impairment in schizophrenia patients (McGurk et al., 2004; Nuechterlein et 
al., 2011). Furthermore, it has been reported that prescribing continuous and 
excessive antipsychotic drug doses leads not only to oversedation and 
extrapyramidal symptoms but also to dopamine supersensitivity psychosis, 
which makes schizophrenia refractory (Chouinard et al., 2008; Iyo et al., 
2013; Yamanaka et al., 2016). Although some unemployed patients with 
schizophrenia may meet the diagnostic criteria for treatment-resistant 
schizophrenia (TRS), which necessitates the administration of high 
CP-equivalent doses (Juarez-Reyes et al., 1995; Lally et al., 2016), our 
finding suggests that prescribing excessive antipsychotic drug doses, defined 
as CP-equivalent doses greater than 600 mg/day, could worsen employment 
prospects for schizophrenia patients. This finding implies that psychiatrists 
should optimize prescribed antipsychotic dosages to avoid cognitive 
impairments and oversedation. 
This study also identified low PANSS negative symptoms scores, male 
sex, short illness durations, and high CDRS total scores as 
employment-related factors for schizophrenia patients. This is consistent 
with previous reports of the relationship between employment in society and 
negative symptoms (Fervaha, 2014; Galderisi, 2013), sex (Tsang et al., 2010), 
and illness durations (Kaneda et al., 2009; Tsang et al., 2010; Wieselgren 
and Lindstorm, 1996). Our finding concerning CDRS total scores is 
consistent with a previous report that highly resilient patients could recover 
from schizophrenia (Hofer et al. 2016). Resilience is a self-healing power 
(Karatsoreos and McEwen, 2011). Moreover, our finding suggests that 
resilience may regulate vocational and social functions (Bozikas et al., 2016). 
Given our finding, future studies should investigate the impact of resilience 
on employment in patients with schizophrenia. 
Our study had several limitations. First, it was cross-sectional, so many 
unemployed schizophrenia patients might have met the diagnostic criteria 
for TRS, considering that they showed higher PANSS scores and higher 
CP-equivalent doses than the employed patients (Juarez-Reyes et al., 1995; 
Lally et al., 2016). Previous studies have documented two TRS patterns, one 
involving poor responses to initial treatment (Lally et al., 2016; Robinson et 
al., 1999; Yamanaka et al., 2016), and the other involving responsiveness to 
initial treatment but the occurrence of recurrent relapses and the later 
development of dopamine supersensitivity psychosis (Iyo et al., 2013; Oda et 
al., 2015). We could not distinguish the two types of TRS, because we only 
examined responsiveness to treatment during the first year. To resolve this 
limitation, prospective cohort studies or randomized controlled trials are 
needed. Second, the time-series SOFAS and GAPS scores were 
retrospectively assessed using medical records and interviews with patients 
and their families. This might have introduced selection and recall bias. 
Third, the study used only a few recruitment sites and consequently involved 
a small and homogeneous sample of participants. Further studies with 
international sites and larger sample sizes are needed to account for cultural 
differences.  
In conclusion, we identified two employment-related factors for 
schizophrenia patients: social functioning improvements in the period 6 to 12 
months after beginning treatment and low-to-moderate daily antipsychotic 
doses. These findings suggest that strong efforts to improve social 
functioning early in treatment and to optimize antipsychotic doses could 
promote future employment for schizophrenia patients. 
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Figure Legends 
Fig. 1. The schema of assessment  
To identify employment-related clinical factors, GAPS and SOFAS were 
assessed at the first visit (T0), 6 months after beginning treatment (T1), and 
12 months after beginning treatment (T2). Daily antipsychotic drug doses, 
psychiatric status, and demographic information were assessed at the 
interview time. Abbreviations: SOFAS = Social and Occupational 
Functioning Assessment Scale; GAPS = Global Assessment of Psychological 
Scale. 
 
Fig. 2.1. SOFAS-measured clinical responses of employed and unemployed 
patients to initial treatment 
Mean SOFAS score change from the baseline (T0) and 95% CIs at T1 and T2. 
The solid line indicates the employed group, and the dotted line indicates the 
unemployed group. The employed group had significantly greater SOFAS 
score changes than the unemployed group. The mean inter-group difference 
was 4.732 (95% CI: 0.837–8.627, p = 0.018) at T1 and 7.048 (95% CI: 2.652–
11.44, p = 0.002) at T2. (*p < 0.05, **p < 0.01). Abbreviations: CI = confidence 
interval; SOFAS = Social and Occupational Functioning Assessment Scale; 
T0 = SOFAS score at first meeting with psychiatrist; T1 = SOFAS score 6 
months after beginning treatment; T2 = SOFAS score 12 months after 
beginning treatment. 
 
Fig. 2.2. GAPS-measured clinical responses of employed and unemployed 
patients to initial treatment 
Mean GAPS score change from the baseline (T0) and 95% CIs at T1 and T2. 
The solid line indicates the employed group, and the dotted line indicates the 
unemployed group. The employed group had significantly greater GAPS 
score changes than the unemployed group. The mean inter-group difference 
was 7.147 (95% CI: 2.776–11.52, p = 0.0015) at T1 and 9.338 (95% CI: 4.554–
14.12, p = 0.0002) at T2. (*p < 0.05, **p < 0.01). Abbreviations: CI = 
confidence interval; GAPS = Global Assessment of Psychological Scale; T0 = 
GAPS score at first meeting with psychiatrist; T1 = GAPS score six months 
after beginning treatment; T2 = GAPS score 12 months after beginning 
treatment. 
 
  
Table 1   
Demographics and clinical characteristics.  
 
 Total 
(N = 235) 
Employment 
(n = 129) 
Unemployment 
(n = 106) p-value 
Age (y) 40.1 (9.9) 39.2 (8.5) 41.2 (11.2) 0.130 
Sex, male/female, n 121/114 70/59 51/55 0.210 
Years of education 13.4 (2.5) 13.8 (2.1) 13.0 (2.8) 0.044 
Work experience, +/-, n 189/35 104/17 85/18 0.301 
Age at onset (y) 25.3 (7.3) 25.3 (7.3) 23.7 (7.3) 0.086 
DUP (m) 21.3 (43.3) 18.9 (37.1) 23.9 (49.1) 0.396 
Disease duration (y) 14.4 (9.6) 12.9 (8.3) 16.1 (10.6) 0.012 
Marital status, +/-, n 64/165 35/88 29/77 0.486 
GAPS 52.8 (18.6) 60.2 (17.8) 44.4 (15.6) <1.0×10-6 
SOFAS 59.2 (17.1) 70.5 (12.3) 46.2 (11.7) <1.0×10-6 
CP-equivalent dose (mg) 528.6 (376.4) 398.1 (278.9) 670.3 (416.5) <1.0×10-6 
PANSS, total 62.0 (19.8) 51.7 (15.0) 74.4 (17.5) <1.0×10-6 
PANSS, positive 14.0 (5.5) 12.2 (4.5) 16.2 (5.8) <1.0×10-6 
PANSS, negative 17.6 (7.0) 13.9 (5.4) 22.0 (6.0) <1.0×10-6 
PANSS, general 30.5 (9.2) 25.7 (7.0) 36.2 (8.1) <1.0×10-6 
CDRS 53.2 (18.6) 58.9 (16.7) 46.5 (18.6) <1.0×10-6 
JCDSS 4.4 (4.4) 3.8 (4.2) 5.2 (4.7) 0.014 
SAI-J 13.4 (4.4) 13.8 (4.3) 13.0 (4.4) 0.172 
All data in this table were assessed at the interviews. Data are means (standard deviations). We examined 
categorical data chi-square tests and continuous data with unpaired t-tests. 
Abbreviations: DUP = duration of untreated psychosis; y = years; m = months; GAPS = Global Assessment of 
Psychological Scale; SOFAS = Social and Occupational Functioning Assessment Scale; CP = chlorpromazine; 
PANSS = Positive and Negative Syndrome Scale; CDRS = Connor–Davidson Resilience Scale; JCDSS = Japanese 
version of the Calgary Depression Scale for Schizophrenia; SAI-J = Japanese version of Schedule for Assessments of 
Insight.  
 
Table 2.1   
Independent variables affecting employment status in a multivariable logistic regression analysis using only 
SOFAS scores.  
Variables Adjusted odds ratio 95% CI p-value 
SOFAS T1-to-T2 change 1.730 1.136-2.634 0.011 
SOFAS T0-to-T1 change 1.070 0.807-1.418 0.638 
CP-equivalents < 600 mg 3.425 1.470-7.981 0.004 
Male sex 3.697 1.462-9.349 0.006 
PANSS, negative 0.799 0.736-0.867 <1.0×10-6 
CDRS 1.046 1.018-1.075 0.001 
Disease duration (y) 0.936 0.893-0.980 0.005 
Years of education 1.032 0.866-1.230 0.724 
SAI-J, total 1.046 0.941-1.163 0.404 
Work history (+) 1.445 0.494-4.230 0.502 
JCDSS 1.085 0.982-1.198 0.107 
T0-to-T1 and T1-to-T2 SOFAS score changes represented clinical responses to initial treatment.  
(χ2 = 113.553, df = 11, p <1.0×10-6, correctly judged 82.5% of the subjects, Cox and Snell R2 = 0.443)  
Abbreviations: CI = confidence interval; SOFAS = Social and Occupational Functioning Assessment Scale; CP = 
chlorpromazine; PANSS = Positive and Negative Syndrome Scale; CDRS = Connor–Davidson Resilience Scale; 
JCDSS = Japanese version of the Calgary Depression Scale for Schizophrenia; SAI-J = Japanese version of 
Schedule for Assessments of Insight. T0 = first meeting with psychiatrist; T1 = 6 months after beginning treatment; 
T2 = 12 months after beginning treatment. 
 
 
Table 2.2   
Independent variables of employment status in a multivariable logistic regression analysis using only GAPS scores  
Variables Adjusted odds ratio 95% CI p-value 
GAPS T1-to-T2 change  1.387 0.927-2.076 0.112 
GAPS T0-to-T1 change 0.984 0.782-1.238 0.890 
CP-equivalents < 600 mg 3.335 1.454-7.649 0.004 
Male sex 3.203 1.315-7.800 0.010 
PANSS, negative 0.796 0.733-0.864 <1.0×10-6 
CDRS 1.042 1.016-1.069 0.002 
Disease duration (y) 0.947 0.904-0.991 0.018 
Years of education 1.034 0.904-0.991 0.698 
SAI-J, total 1.018 0.93-1.13 0.731 
Work history (+) 1.354 0.47-3.48 0.567 
JCDSS 1.067 0.971-1.174 0.179 
(T0-to-T1 and T1-to-T2 GAPS score changes represented clinical responses to initial treatment) 
(χ2 = 108.883, df = 11, p <1.0×10-6, correctly judged 80.9% of the subjects, Cox and Snell R2 = 0.430) 
Abbreviations: CI = confidence interval; GAPS = Global Assessment of Psychological Scale; CP = chlorpromazine; 
PANSS = Positive and Negative Syndrome Scale; CDRS = Connor–Davidson Resilience Scale; JCDSS = Japanese 
version of the Calgary Depression Scale for Schizophrenia; SAI-J = Japanese version of Schedule for Assessments of 
Insight. T0 = first meeting with psychiatrist; T1 = 6 months after beginning treatment; T2 = 12 months after 
beginning treatment. 
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